Skip to main content
. 2017 Jan 27;8(11):17810–17818. doi: 10.18632/oncotarget.14863

Figure 3. Kaplan–Meier survival curves of patients treated with anti-EGFR therapeutics in the microRNA-31 (miR-31)-5p low-expression group (N = 97).

Figure 3

(A) Progression-free survival according to EZH2 expression in the miR-31 low-expression group. (B) Overall survival according to EZH2 expression in the miR-31 low-expression group.